Related references
Note: Only part of the references are listed.Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
T. Andre et al.
ANNALS OF ONCOLOGY (2013)
Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Marc Peeters et al.
CLINICAL CANCER RESEARCH (2013)
PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis
Shuangjie Wu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
C. Mao et al.
ANNALS OF ONCOLOGY (2012)
Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer: A Systematic Review and Meta-analysis
JiaoJiao Ren et al.
DISEASES OF THE COLON & RECTUM (2012)
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Grazia Palomba et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
Gholamreza Safaee Ardekani et al.
PLOS ONE (2012)
Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports
Mariana Petaccia Macedo et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
Chen Mao et al.
MOLECULAR BIOLOGY REPORTS (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
Mi Jung Kwon et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine
G. Smith et al.
BRITISH JOURNAL OF CANCER (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
Jolien Tol et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Microsatellite instability in colorectal cancer-the stable evidence
Eduardo Vilar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study
Hassan Brim et al.
MOLECULAR CANCER (2008)
Differences and evolution of the methods for the assessment of microsatellite instability
L. Laghi et al.
ONCOGENE (2008)
Frequency of defective DNA mismatch repair in colorectal cancer among the Alaska native people
Lisa A. Boardman et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
K-ras mutations in sporadic colorectal tumors in Israel -: Unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes
D Kislitsin et al.
DIGESTIVE DISEASES AND SCIENCES (2002)
Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients
AS Soliman et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
